Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate OncoCyte Corporation before investing.

In this article, we go over a few key elements for understanding OncoCyte Corporation’s stock price such as:

• OncoCyte Corporation’s current stock price and volume
• Why OncoCyte Corporation’s stock price changed recently
• Upgrades and downgrades for OCX from analysts
• OCX’s stock price momentum as measured by its relative strength

About OncoCyte Corporation (OCX)

Before we jump into OncoCyte Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Want to learn more about OncoCyte Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about OncoCyte Corporation.

OncoCyte Corporation’s Stock Price as of Market Close

As of May 19, 2025, 12:08 PM, CST, OncoCyte Corporation’s stock price was $2.850.

OncoCyte Corporation is up 2.15% from its previous closing price of $2.790.

During the last market session, OncoCyte Corporation’s stock traded between $2.808 and $2.940. Currently, there are approximately 25.69 million shares outstanding for OncoCyte Corporation.

OncoCyte Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

OncoCyte Corporation Stock Price History

OncoCyte Corporation’s (OCX) price is currently down 7.47% so far this month.

During the month of May, OncoCyte Corporation’s stock price has reached a high of $3.320 and a low of $2.570.

Over the last year, OncoCyte Corporation has hit prices as high as $4.750 and as low as $1.922. Year to date, OncoCyte Corporation’s stock is up 19.75%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused OncoCyte Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 16, 2025, there were 0 analysts who downgraded OncoCyte Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate OncoCyte Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on OncoCyte Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about OncoCyte Corporation (OCX) by visiting AAII Stock Evaluator.

Relative Price Strength of OncoCyte Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 16, 2025, OncoCyte Corporation has a weighted four-quarter relative price strength of -1.54%, which translates to a Momentum Score of 52 and is considered to be Average.

Want to learn more about how OncoCyte Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

OncoCyte Corporation Stock Price: Bottom Line

As of May 19, 2025, OncoCyte Corporation’s stock price is $2.850, which is up 2.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like OncoCyte Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.